159 related articles for article (PubMed ID: 37503551)
1. Nivolumab for newly and recurrent glioblastoma multiforme treatment: A systematic review and meta-analysis.
Araujo Moura AW; da Silva Rodrigues S; de Oliveira TF; Lobato BM; Pereira Cerize NN; Léo P
J Oncol Pharm Pract; 2023 Oct; 29(7):1736-1747. PubMed ID: 37503551
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
5. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis.
Zhang T; Xin Q; Kang JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6480-6491. PubMed ID: 34787852
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC; Kim BT
J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
10. Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
Lan XY; Li D; Li S; Zhong LZ; Zhao H; Xi YL; Sun ZW
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3522-3533. PubMed ID: 35647833
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M
Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607
[TBL] [Abstract][Full Text] [Related]
12. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for high grade glioma.
Hart MG; Garside R; Rogers G; Stein K; Grant R
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
[TBL] [Abstract][Full Text] [Related]
14. Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.
Grisanti S; Ferrari VD; Buglione M; Agazzi GM; Liserre R; Poliani L; Buttolo L; Gipponi S; Pedersini R; Consoli F; Panciani P; Roca E; Spena G; Triggiani L; Berruti A;
J Neurosurg Sci; 2019 Aug; 63(4):458-467. PubMed ID: 27680966
[TBL] [Abstract][Full Text] [Related]
15. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
Arrieta VA; Duerinck J; Burdett KB; Habashy KJ; Geens W; Gould A; Schwarze JK; Dmello C; Kim KS; Saganty R; Chen L; Moscona A; McCord M; Lee-Chang C; Horbinski CM; Zhang H; Stupp R; Neyns B; Sonabend AM
Clin Cancer Res; 2024 Jan; 30(2):379-388. PubMed ID: 37939133
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
[TBL] [Abstract][Full Text] [Related]
17. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
19. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
20. Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis.
Wahyuhadi J; Immadoel Haq IB; Arifianto MR; Sulistyono B; Meizikri R; Rosada A; Sigit Prakoeswa CR; Susilo RI
Cancer Control; 2022; 29():10732748221079474. PubMed ID: 36748348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
